Latest Regulatory Milestones News

Odyssey Gold’s Stage 1 Scoping Study for the Tuckanarra Project outlines a low-capital, high-margin open-pit mining operation producing 79,000 ounces of gold over 29 months with pre-tax cashflows of A$180 million at A$6,000/oz gold price.

Chariot Resources has secured additional exploration licence transfers in Nigeria and increased its convertible loan to fund regulatory costs, pushing its Nigerian lithium acquisition closer to completion.

Dimerix will provide continued access to its investigational drug DMX-200 for eligible patients with focal segmental glomerular sclerosis after completing the pivotal ACTION3 Phase 3 trial, supporting ongoing treatment ahead of regulatory approval.

Sibelco Silica Pty Ltd has exercised its call option to inject an additional $4.4 million into the Diatreme joint venture, restoring ownership stakes and supporting key project milestones for the Northern Silica Project in Far North Queensland.

Imugene has secured $11.12 million through a placement to advance its allogeneic CAR-T therapy azer-cel after early clinical data showed complete responses in BTKi-resistant lymphoma patients.

Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.

GoldArc Resources has recorded its best grade control drilling results yet at the Mt Stirling Well deposit, reinforcing its resource model and advancing mine planning towards regulatory approval for mining commencement.

PainChek announces the immediate departure of CEO Philip Daffas, with COO Andy Hoggan stepping in as interim leader amid a strategic pivot to boost US market growth following FDA clearance.

Qube Holdings Limited will be removed from the S&P/ASX 200 Index before trading opens on July 9, 2026, following its pending acquisition by Rubik Australia, pending final court approval. Develop Global Limited will take its place in the index.

Racura Oncology has secured Bellberry HREC approval for its HARNESS-1 lung cancer trial, enabling expansion to additional Australian sites including Chris O’Brien Lifehouse and Austin Health, setting the stage for accelerated patient enrolment.

Gold Hydrogen gears up for critical Ramsay Project flow testing of Natural Hydrogen and Helium, while advancing a green methanol feasibility study with Mitsubishi Gas Chemical.

BCAL Diagnostics has acquired a 10.2% stake in Genetic Signatures for $1.39 million, aiming to merge early cancer detection with infectious disease diagnostics and expand its international footprint.